Harpoon Therapeutics filed a registration statement with the US Securities and Exchange Commission (SEC) in relation to its proposed initial public offering (IPO). Harpoon is currently in a quiet period and was unable to comment on the details of its IPO at this time.
Price and quantity of common stock shares have yet to set.
While Harpoon has registered a statement relating to these securities and it has been filed with the SEC, it has not yet become effective.
The clinical-stage immunotherapy company, specializes in the development of T cell engagers.
Harpoon is working with CMC Biologics to develop and manufacture its three lead biologic candidates: HPN424, HPN536, and HPN217. CMC is using its CHEF1 Expression Platform to create clinical and commercial cell lines for the biologics.
The drug candidates were developed through Harpoon’s Tri-specific T-Cell activating construct (TriTEC) platform. The company has plans on moving HPN424 into Phase I trials through the work being done with CMC Biologics.